-
Biotech and Medicare's "seven-year itch": behind the price negotiations for 13 new drugs to abandon
Time of Update: 2023-02-02
After comprehensive strategy, product differentiation competitiveness, market structure and other factors, enterprises have more ideas in the game of medical insurance access, and 13 innovative drugs have voluntarily given up their qualification for drug price negotiation, which is regarded as a clear signal.
-
Domestic hypertension drugs have been approved, and this product is expected to be declared and listed in 2023
Time of Update: 2022-10-02
In the field of hypertension treatment, in addition to 1001, on September 8, Shanghai Pharmaceutical also announced that the "SPH3127 tablets" developed by the company received the "Drug Clinical Trial Approval Notice" approved and issued by the relevant departments, and will start domestic Phase II clinical trials in the near future.
-
In 2022, the market size of innovative drugs will exceed 1,000 billion yuan
Time of Update: 2022-09-21
Affected by multiple resonances such as favorable policies, capital increases, and talent returns, the domestic innovative drug industry has developed rapidly in recent years, and the market size has been expanding, from 799 billion yuan in 2017 to 963.
-
In the next five years, the pharmaceutical company plans to introduce a number of innovative drugs from outside
Time of Update: 2022-09-07
However, the research and development cycle of innovative drugs is long, the investment is high, and the risk is large, and it is not easy to eventually succeed, so the License in (license introduction) model has gradually become one of the main means for domestic pharmaceutical companies to supplement their product pipelines at this stage.
-
Domestic pharmaceutical companies are accelerating their entry into the diabetes drug market
Time of Update: 2022-08-15
Sugar drugs have been approved for marketing one after another At present, driven by multiple factors such as the continuous growth of diabetes patients in China, the successive entry of new diabetes treatment drugs into the medical insurance catalog, and the enhancement of patients' ability to pay, more and more domestic companies have begun to accelerate their deployment in this field.
-
109 listed pharmaceutical companies plan to distribute over 26.3 billion yuan, and the total dividends of this company far exceed the annual net profit
Time of Update: 2022-04-15
According to Zhendong Pharmaceutical's announcement on March 31, the company's 2021 profit distribution plan is: to distribute cash dividends of 27 yuan (tax included) to all shareholders for every 10 shares, with a total cash dividend of more than 2.
-
In the new year, B-class pharmaceutical stocks fell for four consecutive days
Time of Update: 2022-04-15
Due to the high stickiness of the CDMO industry, according to the company's "Follow "Molecules win molecules" strategy, and it is expected that the company's market share in the later stages will gradually increase as these projects funnel into the late clinical and commercial stages .
-
For the first time since its listing, what happened to the former "Big Mac" Harbin Pharmaceutical
Time of Update: 2021-07-08
Harbin Pharmaceuticals explained in the annual report that the losses of the latter two were mainly due to factors such as the medical insurance catalog, the restricted drug catalog, and the quantity purchase, and the inventory of many major products increased several times year-on-year .
-
Shandong: The park is recognized to open up the space for industrial upgrading
Time of Update: 2021-06-24
These 72 chemical parks rely on provincial and municipal key projects to accelerate the conversion of new and old kinetic energy, and promote the development of the chemical industry to high-end, agglomeration, and large-scale development.
-
Imported drugs take the initiative to reduce prices to grab the market in the future or more drugs "self-de-price
Time of Update: 2021-02-16
Incoming drugs actively reduce prices to grab the market more than imported drugs actively apply to reduce the supply price of future or more drugs "self-de-price" days ago, beijing Pharmaceutical C
-
The rising price of vitamin amino acids continues to affect a large number of pharmacies
Time of Update: 2021-02-09
The industry supports normal market competition and environmental protection pressure a certain range of normal price increases, but the hoarding of raw materials and monopoly behavior, will affect a large number of drugstores common drug species, the fate of many low-cost drugs, and the access of ordinary people to medication, is the national economy and people's livelihood issues.
-
Two of the world's top 500 pharmaceutical giants have come under fire for their "snake swallowing elephant" mergers and acquisitions
Time of Update: 2020-09-08
The acquisition, which brought a 60 per cent increase in Takeda's 2019 revenues, successfully pushed pharmaceutical giants such as AstraZeneta and Amway into the top 10 global pharmaceutical companies, but its 2019 profit fell 58.7 per cent year-on-year to $407m, according to earnings reports.
-
Adenosine-inhibited tumor immuno-micro-environmental regulatory drugs (III): CD39 inhibitors
Time of Update: 2020-07-09
Texts To the east with the progress of research on PD-1/PD-L1 and CTL-4 in the field of tumor immunotherapy, immunotherapy has become one of the main directions to combat cancer However, existing c
-
1.5 billion blood lipid drugs Nanjing Changgao Pharmaceuticals is about to enter the bureau
Time of Update: 2020-06-22
Pharmaceutical Network June 18th, June 11, Nanjing Changgao Pharmaceutical's pivastatin calcium tablets (acceptance number CYHS1800199) imitation 4 categories of listing applications into the admini
-
With the amount of procurement of medical representatives pain has just begun
Time of Update: 2020-06-01
The impact wave of the expansion of the 4-plus-7 band purchase appears, whether it is domestic enterprises, or foreign enterprises, the medical delegation team disbanded the news uninterrupted, such a
